Therapeutic potential of RNA interference in drug-resistant cancers

Future Oncology

Volumn 5, Issue 2, 2009, Pages 169-185

  Lage, Hermann ^a  

^a Charité Campus Benjamin Franklin Medical Center   (Germany)

Author keywords

Cancer; Gene therapy; RNA interference; RNAi; ShRNA; SiRNA

Indexed keywords

ABC TRANSPORTER; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CALAA 01; COMPLEMENTARY RNA; CYTOTOXIC AGENT; DOCETAXEL; DOUBLE STRANDED RNA; DOXORUBICIN; LIPOSOME; MICRORNA; MULTIDRUG RESISTANCE PROTEIN 1; PARVOVIRUS VECTOR; PLASMID VECTOR; PROTEIN TYROSINE KINASE INHIBITOR; SHORT HAIRPIN RNA; SIRNA 027; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VALSPODAR;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ARTICLE; BREAST CANCER; CANCER GENE THERAPY; CANCER GENETICS; CANCER INHIBITION; CANCER PATIENT; CANCER RESISTANCE; CLINICAL TRIAL; COLON CANCER; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TREATMENT FAILURE; GENE CASSETTE; GENE SILENCING; GENE TARGETING; HUMAN; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RETINA MACULA AGE RELATED DEGENERATION; RNA INTERFERENCE; RNA TRANSCRIPTION; SOLID TUMOR; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; VIRAL GENE DELIVERY SYSTEM; ANIMAL; DRUG RESISTANCE; GENETICS; NEOPLASM; PHYSIOLOGY; REVIEW;

ANIMALS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; RNA INTERFERENCE;

EID: 66349085063     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.5.2.169     Document Type: Article

References (151)

1. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811 (1998).
2. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498 (2001).
3. Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF, Wu TC: Prospects of RNA interference therapy for cancer. Gene Ther. 13, 464-477 (2006).
4. Hannon GJ: RNA interference. Nature 418, 244-251 (2002).
5. Dorsett Y, Tuschl T: siRNAs: applications in functional genomics-and potential as therapeutics. Nat. Rev. Drug Discov. 3, 318-329 (2004).
6. Martin SE, Caplen NJ: Application of RNA interference in mammalian systems. Annu. Rep. Genomics Hum. Genet. 8, 81-108 (2007).
7. Lage H: Potential applications of RNA interference technology in the treatment of cancer. Fut. Oncol. 1, 103-113 (2005).
8. Rana TM: Illuminating the silence: understanding the structure and function of small RNAs. Nat. Rev. Mol. Cell Biol. 8, 23-36 (2007).
9. Nykanen A, Haley B, Zamore PD: ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell 107, 309-321 (2001).
10. Fuchs U, Borkhardt A: The application of siRNA technology to cancer biology discovery. Adv. Cancer Res. X, 75-102 (2007).
11. Vanhecke D, Janitz M: Functional genomics using high-throughput RNA interference. Drug Discov. Today 10, 205-212 (2005).
12. Altieri DC:.Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 3, 46-54 (2003).
13. Uchida H, Tanaka T, Sasaki K et al.: Adenovirus-mediated transfer.of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol. Ther. 10, 162-171 (2004).
14. Kappler M, Bache M, Bartel F et al.: Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53. Cancer Gene. Ther. 11, 186-193 (2004).
15. Wang Y, Zhu H, Quan L et al.: Downregulation of surviving by RNAi inhibits the growth of esophageal carcinoma cells. Cancer Biol. Ther. 4, 974-978 (2005).
16. Li QX, Zhao J, Liu JY et al.: Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers. Cancer Biol. Ther. 5, 860-866 (2006).
17. Rosa J, Canovas P, Islam A, Altieri DC, Doxsey SJ: Survivin modulates microtubule dynamics and nucleation throughout the cell cycle. Mol. Biol. Cell 17, 1483-1493 (2006).
18. Rahman KV, Li Y, Wang Z, Sarkar SH, Sarkar FH: Gene expression profiling revealed survivin as a target of 3,3′-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells. Cancer Res. 66, 4952-4960 (2006).
19. Biedler JL, Riehm H: Cellular resistance to actinomycin D in chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res. 30, 1174-1184 (1970).
20. Lage H: An overview of cancer multidrug resistance: a still unsolved problem. Cell. Mol. Life Sci. 65, 3145-3167 (2008).
21. Stein U, Walther W: Reversal of ABC transporter-dependent multidrug resistance in cancer a realistic option? Am. J. Cancer 5, 285-297 (2006).
22. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM: Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5, 219-234 (2006).
23. Thomas H, Coley HM: Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10, 159-165 (2003).
24. Greenberg PL, Lee SJ, Advani R et al.: Mitoxantrone, etoposide, and cytarabin with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a Phase III trial (E2995). J. Clin. Oncol. 22, 1078-1086 (2004).
25. van der Holt B, Löwenberg B, Burnett AK et al.: The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106, 2646-2654 (2005).
26. Friedenberg WR, Rue M, Blood EA et al.: Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myelonia (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer 106, 830-838 (2006).
27. Fracasso PM, Goldstein LJ, de Alwis DP et al.: Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clin. Cancer Res. 10, 7220-7228 (2004).
28. Sandier A, Gordon M, De Alwis DP et al.: A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clin. Cancer Res. 10, 3265-3272 (2004).
29. Morschhauser F, Zinzani PL, Burgess M, Sloots L, Bouafia F, Dumontet C: Phase I/II tril of a P-glycoprotein inhibitor Zosuquidar. 3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Leuk. Lymphoma 48, 708-715 (2007).
30. Lage H: MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance. Curr. Drug Targets 7, 813-821 (2006).
31. Sims-Mourtada J, Izzo JG, Ajani J, Chao KS. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene 26, 5674-5679 (2007).
32. Corich L, Aranda A, Carrassa L, Bellarosa C, Ostrow JP, Tiribelli C: The cytotoxic effect of unconjugated bilirubin in human neuroblastoma SH-SY5Y cells is modulated by the expression level of MRP1 but not MDR1. Biochem. J. 417(1), 305-312 (2008).
33. Nieth C, Priebsch A, Stege A, Lage H: Modulatidn of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett. 545, 144-150 (2003).
34. Wu H, Hait WN, Yang JM: Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res. 63, 1515-1519 (2003).
35. Kowalski P, Surowiak P, Lage H: Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP. Mol. Ther. 11, 508-522 (2005).
36. Priebsch A, Rompe F, Tönnies H et al.: Complete reversal of ABCG2-depending atypical multidrug resistance (MDR) by RNA interference in human carcinoma cells. Oligonucleotides 16, 263-274 (2006).
37. Materna V, Stege A, Surowiak P, Priebsch A, Lage H: RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. Biochem. Biophys. Res. Commun. 348, 153-157 (2006).
38. Luo KQ, Chang DC: The-gene-silencing efficiency of siRNA is strongly dependent on the local structure of mRNA at the targeted region. Biochem. Biophys. Res. Commun. 318, 303-310 (2004).
39. Yoshinari K, Miyagishi M, Taira K: Effects on RNAi of the tight structure, sequence and position of the targeted region. Nucleic Acids Res. 32, 691-699 (2004).
40. Kurreck J: siRNA Efficiency: structure or sequence - that is the question. J. Biomed. Biotechnol. 2006(4), 83757 (2006).
41. Duan Z, Brakora KA, Seiden MV: Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol. Cancer Ther. 3, 833-838 (2004).
42. Xu D, Kang H, Fisher M, Juliano RL: Strategies for inhibition of ADR1 gene expression. Mol. Pharmacol. 66, 268-275 (2004).
43. Liscovitch M, Ravid D: A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells. Cancer Lett. 245, 350-352 (2007).
44. Stege A, Priebsch A, Nieth C, Lage H: Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference. Cancer Gene Ther. 11, 699-706 (2004).
45. Yagüe E, Higgins CF, Raguz S: Complete reversal of multidrug resistance by stable. expression of small interfering RNAs targeting MDR1. Gene Ther. 11, 1170-1174 (2004).
46. Li CB, Zhang F, Shi YR, Wei XY, Yang Y, Niu RF: [Reversing multidrug resistance in breast cancer cell line MCF-7/ADR by small interfering RNA.] Ai Zheng 23, 1605-1610 (2004).
47. Xu D, McCarty D, Fernandes A, Fisher M, Samulski RJ, Juliano RL: Delivery of MDR1 small interfering RNA by self-complementary recombinant adeno-associated virus vector. Mol. Ther. 11, 523-530 (2005).
48. Lacroix M: Persistent use of 'false' cell lines. Int. J. Cancer 122, 1-4 (2008).
49. Kaszubiak A, Holm PS, Lage H: Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes. Int. J. Oncol. 31, 419-430 (2007).
50. Shi Z, Liang YJ, Chen ZS et al.: Reversal of MDR1/ P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol. Ther. 5, 39-47 (2006).
51. Pichler A, Zelcer N, Prior JL, Kuil AJ, Piwnica-Worms D: In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin. Cancer Res. 11, 4487-4494 (2005).
52. Matsui Y, Kobayashi N, Nishikawa M, Takakura Y: Sequence-specific suppression of mdr1a/1b expression in mice via RNA interference. Pharm. Res. 22, 2091-2098 (2005).
53. Xiao H, Wu Z, Shen H et al.: In vivo reversal of P-glycoprotein-mediated multidrug resistance by efficient delivery of stealth RNAi. Basic Clin. Pharmacol. Toxicol. 103, 342-348 (2008).
54. Stein U, Walther W, Stege A, Kaszubiak A, Fichtner I, Lage H: Complete in vivo reversal of the multidrug resistance phenotype by jet-injection of anti-MDR1 short hairpin RNA-encoding plasmid DNA. Mol. Ther. 16, 178-186 (2008).
55. Walther W, Siegel R, Kobelt D et al.: Novel jet-injection technology for nonviral intratumoral gene transfer in patients with melanoma and breast cancer. Clin. Cancer Res. 14, 7545-7553 (2008).
56. Walther W, Stein U, Fichtner I, Schlag PM: Low-volume jet injection for efficient nonviral in vivo gene transfer. Mol. Biotechnol. 28, 121-128 (2004).
57. Walther W, Stein U, Fichtner I et al.: Nonviral jet-injection gene transfer for efficient in vivo cytosine deaminase suicide gene therapy of colon carcinoma. Mol. Ther. 12, 1176-1184 (2005).
58. Scotto KW: Transcriptional regulation of ABC drug transporters. Oncogene 22, 7496-7511 (2003).
59. Wu J, Stratford AL, Astanehe A, Dunn SE: YB-1 is a transcription/ translation factor that orchestrates the oncogenome by hardwiring signal transduction to gene expression. Translational Oncogenomics 2, 49-65 (2007).
60. Bargou RC, Jürchott K, Wagener C et al.: Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat. Med. 3, 447-450 (1997).
61. Kaszubiak A, Kupstat A, Müller U, Hausmann R, Holm PS, Lage H: Regulation of MDR1 gene expression in multidrug-resistant cancer cells is independent from YB-1. Biochem. Biophys. Res. Commun. 357, 295-301 (2007).
62. Honma K, Iwao-Koizumi K, Takeshita F et al.: RPN2 gene confers docetaxel resistance in breast cancer. Nat. Med. 14, 939-948 (2008).
63. Voinnet O: Induction and suppression of RNA silencing: insights from viral infections. Nat. Rev. Genet. 6, 206-220 (2005).
64. Zheng ZM, Tang S, Tao M: Development of resistance to RNAi in mammalian cells. Ann. NY Acad. Sci. 1058, 105-118 (2005).
65. Yang W, Wang Q, Howell KL et al.: ADAR1 RNA deaminase limits short interfering RNA efficacy in mammalian cells. J. Biol. Chem. 280, 3946-3953 (2005).
66. Lu S, Cullen BR: Adenovirus VA1 noncoding RNA can inhibit small interfering RNA and MicroRNA biogenesis. J. Virol. 78, 12868-12876 (2004).
67. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR: Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 5, 834-839 (2003).
68. Persengiev SP, Zhu X, Green MR: Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA 10, 12-18 (2004).
69. Williams BR: Role of the double-stranded RNA-activated protein kinase (PKR) in Cell regulation. Biochem. Soc. Trans. 25, 509-513 (1997).
70. Jagus R, Joshi B, Barber GN: PKR, apoptosis and cancer. Int. J. Biochem. Cell Biol. 31, 123-138 (1999).
71. Justesen J, Hartmana R, Kjeldgaard NO: Gene structure and function of the 2′-5′-oligoadenylate synthetase family. Cell. Mol. Life Sci. 57, 1593-1612 (2000).
72. Dong B, Silverman RH: 2-5A-dependent RNase molecules dimerize during activation by 2-5A. J. Biol. Chem. 270, 4133-4137 (1995).
73. Castelli JC, Hassel BA, Maran A et al.: The role of 2′-5′ oligoadenylate-activated ribonuclease L in apoptosis. Cell Death Differ. 5, 313-320 (1998).
74. Hornung V, Guenthner-Biller M, Bourquin C et al.: Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11, 263-270 (2005).
75. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I: Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23, 457-462 (2005).
76. Sioud M: Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J. Mol. Biol. 348, 1079-1090 (2005).
77. Grimm D, Streetz KL, Jopling CL et al.: Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441, 537-541 (2006).
78. Ohrt T, Merkle D, Birkenfeld K, Echeverri CJ, Schwille P: In situ fluorescence analysis demonstrates active siRNA exclusion from the nucleus by Exportin 5. Nucleic Acids Res. 34, 1369-1380 (2006).
79. Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120, 15-20 (2005).
80. Birmingham A, Anderson EM, Reynolds A et al.: 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat. Methods 3, 199-204 (2006).
81. Jackson AL, Bartz SR, Scheirer J et al.: Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21, 635-637 (2003).
82. Semizarov D, Frost L, Sarthy A, Kroeger P, Halbert DN, Fesik SW: Specificity of short interfering RNA determined through gene expression signatures. Proc. Natl Acad. Sci. USA 100, 6347-6352 (2003).
83. Scacheri PC, Rozenblatt-Rosen O, Caplen NJ et al.: Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc. Natl. Acad. Sci. USA 101, 1892-1897 (2004).
84. Fedorov Y, Anderson EM, Birmingham A et al.: Off-target effects by siRNA can induce toxic phenotype. RNA 12, 1188-1196 (2006).
85. Sanguino A, Lopez-Berestein G, Sood AK: Strategies for in vivo siRNA delivery in cancer. Mini Rev. Med. Chem. 8, 248-255 (2008).
86. Soutschek J, Akinc A, Bramlage B et al.: Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173-178 (2004).
87. Zimmermann TS, Lee AC, Akinc A et al.: RNAi-mediated gene silencing in non-human primates. Nature 441, 111-114 (2006).
88. Song E, Zhu P, Lee SK et al.: Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23, 709-717 (2005).
89. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ: Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits rumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 65, 8984-8992 (2005).
90. Kumar P, Ban HS, Kim SS et al.: T cell-specific siRNA delivery suppresses HIV-1, infection in humanized mice. Cell 134, 577-586 (2008).
91. Kumar P, Wu H, McBride JL et al.: Transvascular delivery of small interfering RNA to the central nervous system. Nature 448, 39-43 (2007).
92. Peer D, Park EJ, Morishita Y, Carman CV, Shimaoka M: Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 319, 627-630 (2008).
93. McNamara JO 2nd, Andrechek ER, Wang Y et al.: Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 24, 1005-1015 (2006).
94. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J: Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 6, 443-453 (2007).
95. Kleinman ME, Yamada K, Takeda A et al.: Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452, 591-597 (2008).
96. Scherr M, Battmer K, Winkler T, Heidenreich O, Ganser A, Eder M: Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood 101, 1566-1569 (2003).
97. Wohlbold L, van der Kuip H, Miething C et al.: Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (ST1571). Blood 102, 2236-2239 (2003).
98. Sumimoto H, Miyagishi M, Miyoshi H et al.: Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 23, 6031-6039 (2004).
99. Brummelkamp TR, Bernards R, Agami R: Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2, 243-247 (2002).
100. Ada-Nguema AS, Xenias H, Hofman JM, Wiggins CH, Sheetz MP, Keely PJ: The small GTPase R-Ras regulates organization of actin and drives membrane protrusions through the activity of PLC epsilon. J. Cell Sci. 119, 1307-1319 (2006).
101. Eskandarpour M, Kiaii S, Zhu C, Castro J, Sakko AJ, Hansson J: Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells. Int. J. Cancer 115, 65-73 (2005).
102. Yang G, Thompson JA, Fang B, Liu J: Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumorgrowth in a model of human ovarian cancer. Oncogene 22, 5694-5701 (2003).
103. Holle L, Hicks L, Song W, Holle E, Wagner T, Yu X: Bcl-2 targeting siRNA expressed by a T7 vector system inhibits human tumor cell growth in vitro. Int. J. Oncol. 24, 615-621 (2004).
104. Lima RT, Martins LM, Guimarães, JE, Sambade C, Vascoñcelos MH: Specific downregulation of bcl-2 and xlAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther. 11, 309-316 (2004).
105. Sonoke S, Ueda T, Fujiwara K et al.: Tumor regression in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes. Cancer Res. 68, 8843-8851 (2008).
106. Zhu H, Guo W, Zhang L et al.: Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells. Mol. Cancer Ther. 4, 451-456 (2005).
107. Chen SM, Wang Y, Xiao BK, Tao ZZ: Effect of blocking VEGF, hTERT and Bcl-xl by multiple shRNA expression vectors on the human laryngeal squamous carcinoma xenograft in nude mice. Cancer Biol. Ther. 7, 734-739 (2008).
108. Zhen HN, Li LW, Zhang W et al.: Short hairpin RNA targeting survivin inhibits growth and angiogenesis of glioma U251 cells. Int. J. Oncol. 31, 1111-1117 (2007).
109. McManus DC, Lefebvre CA, Cherton-Horvat G et al.: Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene 23, 8105-8117 (2004).
110. Zhang S, Ding F, Luo A et al.: XIAP is highly expressed in esophageal cancer and its downregulation by RNAi sensitizes esophageal carcinoma cell lines to chemotherapeutics. Cancer Biol. Ther. 6, 973-980 (2007).
111. Yuan J, Krämer A, Matthess Y et al.: Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo. Oncogene 25, 1753-1762 (2006).
112. Purow BW, Haque RM, Noel MW et al.: Expression of Notch-1 and its ligands, δ-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res. 65, 2353-2363 (2005).
113. DuPree EL, Mazumder S, Almasan A: Genotoxic stress induces expression of E2F4, leading to its association with p130 in prostate carcinoma cells. Cancer Res. 64, 4390-4393 (2004).
114. Yamato K, Fen J, Kobuchi H et al. Induction of cell death in human papillomavirus 18-positive cervical cancer cells by E6 siRNA. Cancer Gene Ther. 13, 234-241 (2006).
115. Yimato K, Yamada T, Kizaki M et al.: New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer. Cancer Gene Ther. 15, 140-153 (2008).
116. Li S, Crothers J, Haqq CM, Blackburn EH: Cellular and gene expression responses involved in the rapid growth inhibition of human cancer cells by RNA interference-mediated depletion of telomerase RNA. J. Biol. Chem. 280, 23709-23717 (2005).
117. Zou L, Zhang P, Luo C, Tu Z: shRNA-targeted hTERT suppress cell proliferation of bladder cancer by inhibiting telomerase activity. Cancer Chemother. Pharmacol. 57, 328-334 (2006).
118. Edovitsky E, Elkin M, Zcharia E, Peretz T, Vlodavsky I: Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J. Natl Cancer Inst. 96, 1219-1230 (2004).
119. Zhang Y, Li L, Wang Y et al.: Downregulating the expression of heparanase inhibits the invasion, angiogenesis and metastasis of human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 358, 124-129 (2007).
120. Wyatt CA, Geoghegan JC, Brinckerhoff CE: Short hairpin RNA-mediated inhibition of matrix metalloproteinase-1 in MDA-231 cells: effects on matrix destruction and tumor growth. Cancer Res. 65, 11101-11108 (2005).
121. Chetty C, Bhoopathi P, Joseph P, Chittivelu S, Rao JS, Lakka S: Adenovirus-mediated small interfering RNA against matrix metalloproteinase-2 suppresses tumor growth and lung metastasis in mice. Mol. Cancer Ther. 5, 2289-2299 (2006).
122. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS: Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice. Clin. Cancer Res. 13, 4051-4060 (2007).
123. Zhang L, Yang N, Mohamed-Hadley A, Rubin SC, Coukos G: Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochem. Biophys. Res. Commun. 303, 1169-1178 (2003).
124. Guan H, Zhou Z, Wang H, Jia SF, Liu W, Kleinerman ES: A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clin. Cancer Res. 11, 2662-2669 (2005).
125. Shao SL, Sun YY, Li XY et al.: The reversion effect of the RNAi-silencing MDR1 gene on multidrug resistance of the leukemia cell HT9. Cell Biol. Int. 32, 893-898 (2008).
126. Arora S, Yang JM, Utsumi R, Okamoto T, Kitayama T, Hait WN: P-glycoprotein mediates resistance to histidine kinase inhibitors. Mol. Pharmacol. 66, 460-467 (2004).
127. Stierlé V, Laigle A, Jollès B: The reduction of P-glycoprotein expression by small interfering RNAs is improved in exponentially growing cells. Oligonucleotides 14, 191-198 (2004).
128. Stierlé V, Laigle A, Jollès B: Modulation of MDR1 gene expression in multidrug resistant MCF7 cells by low concentrations of small interfering RNAs. Biochem. Pharmacol. 70, 1424-1430 (2005).
129. Li L, Xu J, Min T, Huang W: Reversal of MDR1 gene-dependent multidrug resistance using low concentration of endonuclease-prepared small interference RNA. Eur. J. Pharmacol. 536, 93-97 (2006).
130. Stierlé V, Laigle A, Jollès B: Modulation of the efficiency of a siRNA directed against MDR1 expression in MCF7 cells when combined with a second siRNA. Biochimie 89, 1033-1036 (2007).
131. Logashenko EB, Vladimirova AV, Repkova MN, Venyaminova AG, Chernolovskaya EL, Vlassov VV: Silencing of MDR1 gene in cancer cells by siRNA. Nucleosides Nucleotides Nucleic Acids 23, 861-866 (2004).
132. Peng Z, Xiao Z, Wang Y et al.: Reversal of P-glycoprotein-mediated multidrug resistance with small interference RNA (siRNA) in leukemia cells. Cancer Gene Ther. 11, 707-712 (2004).
133. Gu JW, Zhang T, Chen BB, Lu Y, Lin GW: [Functional study of mdr1 and GSTpi expression reversed by hairpin siRNA in K562/A02 cell line.] Zhonghua Xue Ye Xue Za Zhi 27, 17-20 (2006).
134. Xiao XB, Xie ZX, Qin Q. [Reversal of multidrug resistance by MDR1 shRNA expression vector in human leukemia K562/A02 cells.] Zhonghua Zhong Liu Za Zhi 28, 422-425 (2006).
135. Lim MN, Lau NS, Chang KM, Leong CF, Zakaria Z: Modulating multidrug resistance gene in leukaemia cells by short interfering RNA. Singapore Med. J. 48, 932-938 (2007).
136. Wei HL, Gan LP, Jing T, Zhao HS, Yi J, Sun J, Han J: [siRNA silences MDR1 gene expression and reverses apoptosis resistance of K562/ADM cells line]. Zhonghua Xue Ye Xue Za Zhi 28, 388-390 (2007).
137. Widmer N, Rumpold H, Untergasser G, Fayet A, Buclin T, Decosterd LA: Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels. Leukemia 21, 1561-1562 (2007).
138. Celius T, Garberg P, Lundgren B: Stable suppression of MDR1 gene expression and function by RNAi in Caco-2 cells. Biochem. Biophys. Res. Commun. 324, 365-371 (2004).
139. Watanabe T, Onuki R, Yamashita S, Taira K, Sugiyama Y: Construction of a functional transporter analysis system using MDR1 knockdown Caco-2 cells. Pharm. Res. 22, 1287-1293 (2005).
140. Park SY, Lee W, Lee J, Kim IS: Combination gene therapy using multidrug resistance (MDR1) gene shRNA and herpes simplex virus-thymidine kinase. Cancer Lett. 261, 205-214 (2008).
141. Gao FL, Wang F, Wu JL, Le XP, Zhang QX: [Screening effective sequences of small interfering RNAs targeting MDR1 gene in human gastric cancer SGC7901/VCR cells.] Zhonghua Zhong Liu Za Zhi 28, 178-182 (2006).
142. Zhao P, Zhang Y, Sun M, He Y: Reversion of multidrug resistance in human glioma by RNA interference. Neurol. Res. 30, 562-566 (2008).
143. Ren YY: [Suppression of MDR1 expression and restoration of sensitivity to chemotherapy in multidrug-resistant hepatocellular carcinoma cell line Bcl7402/5-Fu by RNA interference.] Zhong Nan Da Xue Xue Bao Yi Xue Ban 31, 872-876 (2006).
144. Chen XP, Wang Q, Guan J, Huang ZY, Zhang WG, Zhang BX: Reversing multidrug resistance by RNA interference through the suppression of MDR1 gene in human hepatoma cells. World J. Gastroenterol. 12, 3332-3337 (2006).
145. Gan HZ, Zhang GZ, Zhao JS et al.: Reversal of MDR1 gene-dependent multidrug resistance using short hairpin RNA expression yectors. Chin. Med. J. (Engl). 118, 893-902 (2005).
146. Lou JY, Peng ZL, Zheng Y, Wang H, He B, Wang HJ: [Reversal of multi-drug resistance in ovarian cancer cell by RNA interference.] Zhongbua Fu Chan Ke Za Zhi 41, 413-416 (2006).
147. Song ZY, Hu HY, Deng L, Wu BY, Guo KY, Zhang MX: [Effect of small interfering RNA targeting multidrug resistance-related protein and bcl-2 on drug resistance and apoptosis of K562 and K562/ADM cells.] Nan Fang Yi Ke Da Xue Xue Bao 28, 1306-1308 (2008).
148. Ma JJ, Chen BL, Xin XY: Inhibition of multi-drug resistance of ovarian carcinoma by small interfering RNA targeting to MRP2 gene. Arch. Gynecol. Obstet. 279(2), 149-157 (2009).
149. Lv H, He Z, Liu X, Yuan J, Yu Y, Chen Z: Reversal of BCRP-mediated multidrug resistance by stable expression of small interfering RNAs. J. Cell. Biochem. 102, 75-81 (2007).
150. Li WT, Zhou GY, Song XR, Chi WL, Ren RM, Wang XW: Modulation of BCRP mediated atypical multidrug resistance phenotype by RNA interference. Neoplasma 52, 219-224 (2005).
151. Ee PL, He X, Ross DD, Beek WT: Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference. Mol. Cancer Ther. 3, 1577-1583 (2004).